TheraRadar
← Back
Data updated: Jun 28, 2026

Ferring Pharmaceuticals A/S

Biotech
OncologyImmunologyGastroenterology Execution: Excellent

Ferring Pharmaceuticals A/S is a biotechnology company focused on Oncology, Immunology, Gastroenterology.

2022
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

Ferring Pharmaceuticals A/S at a Glance

  • Strong track record with 84% execution quality across 129 trials
  • Fast trial execution (18 months median completion)

Ferring Pharmaceuticals A/S's Key Drugs

Ferring Pharmaceuticals A/S's core commercial portfolio centers on Adstiladrin, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.

Adstiladrin
IFN-alpha Approved 2022

Ferring Pharmaceuticals A/S's Recent FDA Approvals

New NDA/BLA approvals for Ferring Pharmaceuticals A/S over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

Ferring Pharmaceuticals A/S's Therapeutic Areas

Ferring Pharmaceuticals A/S's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 57%
0 drugs Phase 3: 19 Phase 2: 2 Phase 1: 4
Immunology 23%
0 drugs Phase 3: 8 Phase 1: 2
Gastroenterology 15%
0 drugs Phase 3: 5 Phase 1: 2
Infectious Disease 3%
0 drugs Phase 3: 1
Metabolic 3%
0 drugs Phase 3: 1

Ferring Pharmaceuticals A/S Pipeline Snapshot

Ferring Pharmaceuticals A/S has 44 active clinical programs from ClinicalTrials.gov — 34 Phase 3, 2 Phase 2 and 8 Phase 1.

34
Phase 3
2
Phase 2
8
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Adstiladrin leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 62/72 completed
  • • Speed: 18 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges